Michael J Haller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3737716/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cost-Effectiveness of Low-Dose Antithymocyte Globulin Versus Other Immunotherapies for Treatment of New-Onset Type 1 Diabetes. Diabetes Technology and Therapeutics, 2022, 24, 258-267.	2.4	2
2	Heterogeneity of DKA Incidence and Age-Specific Clinical Characteristics in Children Diagnosed With Type 1 Diabetes in the TEDDY Study. Diabetes Care, 2022, 45, 624-633.	4.3	7
3	Challenges and Opportunities in Using Telehealth for Diabetes Care. Diabetes Spectrum, 2022, 35, 33-42.	0.4	17
4	The association of physical activity to oral glucose tolerance test outcomes in multiple autoantibody positive children: The <scp>TEDDY</scp> Study. Pediatric Diabetes, 2022, 23, 1017-1026.	1.2	1
5	Image-Based Machine Learning Algorithms for Disease Characterization in the Human Type 1 Diabetes Pancreas. American Journal of Pathology, 2021, 191, 454-462.	1.9	19
6	Adherence to oral glucose tolerance testing in children in stage 1 of type 1 diabetes: The <scp>TEDDY</scp> study. Pediatric Diabetes, 2021, 22, 360-368.	1.2	8
7	Genetic Composition and Autoantibody Titers Model the Probability of Detecting C-Peptide Following Type 1 Diabetes Diagnosis. Diabetes, 2021, 70, 932-943.	0.3	8
8	Exocrine Pancreatic Enzymes Are a Serological Biomarker for Type 1 Diabetes Staging and Pancreas Size. Diabetes, 2021, 70, 944-954.	0.3	20
9	Integrative analyses of TEDDY Omics data reveal lipid metabolism abnormalities, increased intracellular ROS and heightened inflammation prior to autoimmunity for type 1 diabetes. Genome Biology, 2021, 22, 39.	3.8	22
10	How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic?. Diabetes, 2021, 70, 1021-1028.	0.3	2
11	Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report. Diabetes, 2021, 70, 1123-1129.	0.3	11
12	Feasibility of the Web-Based Intervention Designed to Educate and Improve Adherence Through Learning to Use Continuous Glucose Monitor (IDEAL CGM) Training and Follow-Up Support Intervention: Randomized Controlled Pilot Study. JMIR Diabetes, 2021, 6, e15410.	0.9	4
13	Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes. Diabetes Care, 2021, 44, 1480-1490.	4.3	56
14	Delayed diagnosis of diabetic ketoacidosis and associated mortality during the COVID â€19 pandemic. Journal of Diabetes, 2021, 13, 837-839.	0.8	0
15	Democratizing type 1 diabetes specialty care in the primary care setting to reduce health disparities: project extension for community healthcare outcomes (ECHO) T1D. BMJ Open Diabetes Research and Care, 2021, 9, e002262.	1.2	20
16	Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample. Diabetologia, 2021, 64, 2432-2444.	2.9	8
17	An Evaluation of Two Capillary Sample Collection Kits for Laboratory Measurement of HbA1c. Diabetes Technology and Therapeutics, 2021, 23, 537-545.	2.4	31
18	Apparent Clitoromegaly in Healthy Female Newborn. Pediatrics in Review, 2021, 42, 173-176.	0.2	1

#	Article	IF	CITATIONS
19	A unified mathematical model of thyroid hormone regulation and implication for personalized treatment of thyroid disorders. Journal of Theoretical Biology, 2021, 528, 110853.	0.8	8
20	Factors Associated With the Decline of C-Peptide in a Cohort of Young Children Diagnosed With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1380-e1388.	1.8	7
21	Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. BMJ Open, 2021, 11, e053669.	0.8	4
22	Teaching Type 1 Diabetes: Creating Stakeholder Engagement in Biomedical Careers Through Undergraduate Research Curriculum. Medical Science Educator, 2020, 30, 69-73.	0.7	1
23	Temporal Analysis of Amylase Expression in Control, Autoantibody-Positive, and Type 1 Diabetes Pancreatic Tissues. Diabetes, 2020, 69, 60-66.	0.3	18
24	Estimated Lifetime Economic Burden of Type 1 Diabetes. Diabetes Technology and Therapeutics, 2020, 22, 121-130.	2.4	50
25	Insulin-Like Growth Factor Dysregulation Both Preceding and Following Type 1 Diabetes Diagnosis. Diabetes, 2020, 69, 413-423.	0.3	29
26	The Neighborhood Deprivation Index and Provider Geocoding Identify Critical Catchment Areas for Diabetes Outreach. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3069-3075.	1.8	22
27	Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes. New England Journal of Medicine, 2020, 383, 2007-2017.	13.9	137
28	Use of Ecological Momentary Assessment to Measure Self-Monitoring of Blood Glucose Adherence in Youth With Type 1 Diabetes. Diabetes Spectrum, 2020, 33, 280-289.	0.4	8
29	Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes. Diabetes Technology and Therapeutics, 2020, 22, 948-953.	2.4	41
30	Human Regulatory T Cells From Umbilical Cord Blood Display Increased Repertoire Diversity and Lineage Stability Relative to Adult Peripheral Blood. Frontiers in Immunology, 2020, 11, 611.	2.2	23
31	Commercially Available Insulin Products Demonstrate Stability Throughout the Cold Supply Chain Across the U.S Diabetes Care, 2020, 43, 1360-1362.	4.3	4
32	Clinical trial data validate the C-peptide estimate model in type 1 diabetes. Diabetologia, 2020, 63, 885-886.	2.9	3
33	Innate inflammation drives NK cell activation to impair Treg activity. Journal of Autoimmunity, 2020, 108, 102417.	3.0	36
34	Primary Care Providers in California and Florida Report Low Confidence in Providing Type 1 Diabetes Care. Clinical Diabetes, 2020, 38, 159-165.	1.2	18
35	Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials. Diabetes, 2020, 69, 1827-1832.	0.3	23
36	Exocrine Pancreas Dysfunction in Type 1 Diabetes. Endocrine Practice, 2020, 26, 1505-1513.	1.1	18

#	Article	IF	CITATIONS
37	Human Factors Associated with Continuous Glucose Monitor Use in Patients with Diabetes: A Systematic Review. Diabetes Technology and Therapeutics, 2019, 21, 589-601.	2.4	22
38	Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. Diabetes, 2019, 68, 1267-1276.	0.3	80
39	Objectively Measured Adherence in Adolescents With Type 1 Diabetes on Multiple Daily Injections and Insulin Pump Therapy. Journal of Pediatric Psychology, 2019, 44, 21-31.	1.1	22
40	Relative Pancreas Volume Is Reduced in First-Degree Relatives of Patients With Type 1 Diabetes. Diabetes Care, 2019, 42, 281-287.	4.3	80
41	Predicting progression to type 1 diabetes from ages 3 to 6 in islet autoantibody positive TEDDY children. Pediatric Diabetes, 2019, 20, 263-270.	1.2	31
42	Designing Online and Mobile Diabetes Education for Fathers of Children With Type 1 Diabetes: Mixed Methods Study. JMIR Diabetes, 2019, 4, e13724.	0.9	9
43	Family adjustment to diabetes diagnosis in children: Can participation in a study on type 1 diabetes genetic risk be helpful?. Pediatric Diabetes, 2018, 19, 1025-1033.	1.2	27
44	Presymptomatic screening for autoimmune β-cell disorder: Baby steps toward prevention?. Pediatric Diabetes, 2018, 19, 11-13.	1.2	1
45	Application of a Genetic Risk Score to Racially Diverse Type 1 Diabetes Populations Demonstrates the Need for Diversity in Risk-Modeling. Scientific Reports, 2018, 8, 4529.	1.6	59
46	Gestational respiratory infections interacting with offspring HLA and CTLA-4 modifies incident β-cell autoantibodies. Journal of Autoimmunity, 2018, 86, 93-103.	3.0	22
47	Pandemrix® vaccination is not associated with increased risk of islet autoimmunity or type 1 diabetes in the TEDDY study children. Diabetologia, 2018, 61, 193-202.	2.9	18
48	Immune Mechanisms and Pathways Targeted in Type 1 Diabetes. Current Diabetes Reports, 2018, 18, 90.	1.7	29
49	ISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescents. Pediatric Diabetes, 2018, 19, 20-27.	1.2	89
50	Understanding Pre-Type 1 Diabetes: The Key to Prevention. Frontiers in Endocrinology, 2018, 9, 70.	1.5	25
51	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care, 2018, 41, 1917-1925.	4.3	114
52	Transition Education for Young Adults With Type 1 Diabetes: Pilot Feasibility Study for a Group Telehealth Intervention. JMIR Diabetes, 2018, 3, e10909.	0.9	11
53	Premeal insulin decreases arterial stiffness in children with type 1 diabetes. Pediatric Diabetes, 2017, 18, 311-314.	1.2	4
54	Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy. Molecular Therapy - Methods and Clinical Development, 2017, 4, 178-191.	1.8	62

#	Article	IF	CITATIONS
55	Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls. Pediatric Diabetes, 2017, 18, 794-802.	1.2	39
56	Serum Trypsinogen Levels in Type 1 Diabetes. Diabetes Care, 2017, 40, 577-582.	4.3	40
57	T Cell Receptor Profiling in Type 1 Diabetes. Current Diabetes Reports, 2017, 17, 118.	1.7	26
58	High Illicit Drug Abuse and Suicide in Organ Donors With Type 1 Diabetes. Diabetes Care, 2017, 40, e122-e123.	4.3	6
59	Analgesic antipyretic use among young children in the TEDDY study: no association with islet autoimmunity. BMC Pediatrics, 2017, 17, 127.	0.7	17
60	Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity. Diabetologia, 2017, 60, 35-38.	2.9	28
61	Lactobacillus johnsonii N6.2 Modulates the Host Immune Responses: A Double-Blind, Randomized Trial in Healthy Adults. Frontiers in Immunology, 2017, 8, 655.	2.2	73
62	Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes. Diabetes, 2016, 65, 3765-3775.	0.3	62
63	The DIPP project: 20 years of discovery in type 1 diabetes. Pediatric Diabetes, 2016, 17, 5-7.	1.2	19
64	The influence of type 1 diabetes on pancreatic weight. Diabetologia, 2016, 59, 217-221.	2.9	88
65	Growth and Risk for Islet Autoimmunity and Progression to Type 1 Diabetes in Early Childhood: The Environmental Determinants of Diabetes in the Young Study. Diabetes, 2016, 65, 1988-1995.	0.3	49
66	Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proceedings of the United States of America, 2016, 113, E1826-34.	3.3	492
67	Updates on Immune Therapies in Type 1 Diabetes. European Endocrinology, 2016, 12, 89.	0.8	7
68	Can We Prevent Type 1 Diabetes?. Current Diabetes Reports, 2015, 15, 86.	1.7	4
69	Screening for T1D risk to reduce DKA is not economically viable. Pediatric Diabetes, 2015, 16, 565-572.	1.2	25
70	Acute Versus Progressive Onset of Diabetes in NOD Mice: Potential Implications for Therapeutic Interventions in Type 1 Diabetes. Diabetes, 2015, 64, 3885-3890.	0.3	42
71	Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. Journal of Clinical Investigation, 2015, 125, 448-455.	3.9	140
72	Phases of type 1 diabetes in children and adolescents. Pediatric Diabetes, 2014, 15, 18-25.	1.2	48

#	Article	IF	CITATIONS
73	Effect of a single autologous cord blood infusion on beta-cell and immune function in children with new onset type 1 diabetes: a non-randomized, controlled trial. Pediatric Diabetes, 2014, 15, 100-109.	1.2	30
74	A contrast between children and adolescents with excellent and poor control: the T1D exchange clinic registry experience. Pediatric Diabetes, 2014, 15, 110-117.	1.2	102
75	Thyroid storm following radioactive iodine (RAI) therapy for pediatric graves disease. American Journal of Case Reports, 2014, 15, 212-215.	0.3	13
76	The autoimmune disease-associated SNP rs917997 of IL18RAP controls IFNÎ ³ production by PBMC. Journal of Autoimmunity, 2013, 44, 8-12.	3.0	22
77	Autologous Umbilical Cord Blood Infusion followed by Oral Docosahexaenoic Acid and Vitamin D Supplementation for C-Peptide Preservation in Children with Type 1 Diabetes. Biology of Blood and Marrow Transplantation, 2013, 19, 1126-1129.	2.0	47
78	Update on Global Intervention Studies in Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America, 2012, 41, 695-712.	1.2	3
79	Type 1 Diabetes: Current Concepts in Epidemiology, Pathophysiology, Clinical Care, and Research. Current Problems in Pediatric and Adolescent Health Care, 2012, 42, 269-291.	0.8	91
80	Neonatal diabetes mellitus and congenital diaphragmatic hernia: coincidence or concurrent etiology?. International Journal of Pediatric Endocrinology (Springer), 2012, 2012, 21.	1.6	5
81	Use of a precious resource: Parental decision making about using autologous umbilical cord blood in studies involving young children with type 1 diabetes. Contemporary Clinical Trials, 2011, 32, 524-529.	0.8	2
82	Reduced Prevalence of Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in Young Children Participating in Longitudinal Follow-Up. Diabetes Care, 2011, 34, 2347-2352.	4.3	133
83	Autologous Umbilical Cord Blood Transfusion in Young Children With Type 1 Diabetes Fails to Preserve C-Peptide. Diabetes Care, 2011, 34, 2567-2569.	4.3	61
84	Islet Autoantibody Seroconversion in the DPT-1 Study. Diabetes Care, 2011, 34, 358-362.	4.3	18
85	Development of Autoantibodies in the TrialNet Natural History Study. Diabetes Care, 2011, 34, 1897-1901.	4.3	55
86	Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area. Journal of Diabetes and Its Complications, 2010, 24, 163-167.	1.2	20
87	Arterial Stiffness, Lipoprotein Particle Size, and Lipoprotein Particle Concentration in Children with Type 1 Diabetes. Journal of Pediatric Endocrinology and Metabolism, 2010, 23, 661-7.	0.4	11
88	Efforts to Prevent and Halt Autoimmune Beta Cell Destruction. Endocrinology and Metabolism Clinics of North America, 2010, 39, 527-539.	1.2	10
89	Pediatric Atorvastatin in Diabetes Trial (PADIT): A Pilot Study to Determine the Effect of Atorvastatin on Arterial Stiffness and Endothelial Function in Children with Type 1 Diabetes Mellitus. Journal of Pediatric Endocrinology and Metabolism, 2009, 22, 65-8.	0.4	36
90	Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus. JAMA - Journal of the American Medical Association, 2009, 302, 624.	3.8	9

#	Article	IF	CITATIONS
91	Serum Monocyte Chemoattractant Protein-1 Concentrations Associate With Diabetes Status but Not Arterial Stiffness in Children With Type 1 Diabetes. Diabetes Care, 2009, 32, 465-467.	4.3	18
92	Immune Depletion With Cellular Mobilization Imparts Immunoregulation and Reverses Autoimmune Diabetes in Nonobese Diabetic Mice. Diabetes, 2009, 58, 2277-2284.	0.3	68
93	Vascular Dysfunction in Glycogen Storage Disease Type I. Journal of Pediatrics, 2009, 154, 588-591.	0.9	20
94	In Pursuit Of Lower A1c. Journal of Pediatrics, 2009, 155, 161-162.	0.9	6
95	The road not taken: A path to curing type 1 diabetes?. European Journal of Immunology, 2009, 39, 2054-2058.	1.6	6
96	Autologous Umbilical Cord Blood Transfusion in Very Young Children With Type 1 Diabetes. Diabetes Care, 2009, 32, 2041-2046.	4.3	87
97	What's in a name? Thyroid autoimmunity in obese patients with T1D. Pediatric Diabetes, 2008, 9, 263-265.	1.2	1
98	Autologous umbilical cord blood infusion for type 1 diabetes. Experimental Hematology, 2008, 36, 710-715.	0.2	136
99	Adverse Impact of Temperature and Humidity on Blood Glucose Monitoring Reliability: A Pilot Study. Diabetes Technology and Therapeutics, 2007, 9, 1-9.	2.4	39
100	NOS3 Polymorphisms Are Associated With Arterial Stiffness in Children With Type 1 Diabetes. Diabetes Care, 2007, 30, 689-693.	4.3	22
101	Type 1 diabetes intervention trials 2007: where are we and where are we going?. Current Opinion in Endocrinology, Diabetes and Obesity, 2007, 14, 283-287.	1.2	30
102	Correlation between radial artery tonometry- and fingertip tonometry-derived augmentation index in children with type 1 diabetes. Diabetes and Vascular Disease Research, 2007, 4, 66-66.	0.9	25
103	Peripheral artery tonometry demonstrates altered endothelial function in children with type 1 diabetes. Pediatric Diabetes, 2007, 8, 193-198.	1.2	119
104	Endocrine complications of childhood cancer therapy: evaluation and management. Pediatric Endocrinology Reviews, 2007, 4, 196-204.	1.2	3
105	Arterial thrombosis resulting in amputation in a child with poorly controlled type 1 diabetes and heterozygous Factor V Leiden mutation. Pediatric Diabetes, 2006, 7, 229-231.	1.2	9
106	Serum Superoxide Dismutase Activity and Nitric Oxide Do Not Correlate with Arterial Stiffness in Children with Type 1 Diabetes Mellitus. Journal of Pediatric Endocrinology and Metabolism, 2006, 19, 267-9.	0.4	6
107	CD3-Antibody Therapy in New-Onset Type 1 Diabetes Mellitus. New England Journal of Medicine, 2005, 353, 2086-2087.	13.9	7
108	Type 1 Diabetes Mellitus: Etiology, Presentation, and Management. Pediatric Clinics of North America, 2005, 52, 1553-1578.	0.9	140

#	Article	IF	CITATIONS
109	Radial Artery Tonometry Demonstrates Arterial Stiffness in Children With Type 1 Diabetes. Diabetes Care, 2004, 27, 2911-2917.	4.3	141
110	Predictors of control of diabetes: monitoring may be the key. Journal of Pediatrics, 2004, 144, 660-661.	0.9	140